Oligodendrocytes are the myelin-forming cells of the central nervous system. Oligodendrocyte loss and failure of myelin development result in serious human disorders, including multiple sclerosis. Previously, using oligodendrocyte progenitor cells, we have shown that donepezil, which is an acetylcholinesterase inhibitor developed for the treatment of Alzheimer's disease, stimulates myelin gene expression and oligodendrocyte differentiation. Here, we aimed to analyze the effects of donepezil on primary mouse embryonic neural stem cells (NSCs). Donepezil treatment led to impaired self-renewal ability and increased apoptosis. These effects appeared to be mediated through the Akt/Bad signaling pathway. Using neurosphere differentiation analysis, we observed that donepezil leads to reduced numbers of astrocytes and increased numbers of oligodendrocytes and neurons. Consistent with this finding, mRNA and protein levels for the oligodendrocyte markers myelin-associated glycoprotein, 2 0 , 3 0 -cyclic-nucleotide 3 0 -phosphodiesterase (CNPase), and myelin basic protein, as well as the neuronal marker b-tubulin type III (Tuj1) were up-regulated. In contrast, the expression of the astrocyte marker glial fibrillary acidic protein (GFAP) was downregulated by donepezil in a dose-and time-dependent manner. Moreover, donepezil increased oligodendrocyte differentiation, resulting in a reduction in the differentiation of NSCs into astrocytes, by suppressing the activation of signal transducer and activator of transcription 3 (STAT3), SMAD1/ 5/9, and the downstream target gene GFAP, even under astrocyte-inducing conditions. These results suggest that efficient differentiation of NSCs into oligodendrocytes by donepezil may indicate a novel therapeutic role for this drug in promoting repair in demyelinated lesions in addition to its role in preventing astrogenesis.
Neural stem cells (NSCs) are capable of self-renewal and differentiation into multiple cell types, including neurons, astrocytes, and oligodendrocytes Weiss 1992, 1996) . Oligodendrocytes are myelin-forming cells, which arise from oligodendrocyte progenitor cells (OPCs) that originate in restricted regions of the subventricular zone (SVZ) of the developing brain and spinal cord (Menn et al. 2006; Richardson et al. 2006) . OPCs may also be generated by multipotent NSCs of the adult SVZ (Levison and Goldman 1993; Doetsch et al. 1999) . These stem/progenitor cells persist in the adult mammalian central nervous system (CNS) throughout life (Young et al. 2013) . Loss of myelinating oligodendrocytes and failure of myelin development leads to serious human disorders, including multiple sclerosis (MS) (Goldman et al. 2012) . In the adult CNS in MS, NSCs and OPCs migrate to demyelinated areas. This is also observed in animal models of MS, such as experimental autoimmune encephalomyelitis (EAE) and in cuprizoneinduced demyelination. However, these progenitor cells fail to differentiate into myelin-forming oligodendrocytes and thus do not contribute to remyelination, possibly because of the inhibitory signals within demyelinated lesions (Wolswijk 1998 (Wolswijk , 2002 Chang et al. 2000 Chang et al. , 2002 Totoiu and Keirstead 2005; Kuhlmann et al. 2008; Kremer et al. 2011) . Therefore, pharmacological activation and stimulation of endogenous NSCs or OPCs to differentiate into mature, myelin-producing oligodendrocytes may be beneficial for the treatment of oligodendrocyte and myelin dysfunction.
Acetylcholinesterase inhibitors like donepezil, galantamine, and rivastigmine increase the levels and the duration of action of the neurotransmitter acetylcholine in the brain (Sugimoto et al. 2000) . These inhibitors are commonly used to treat Alzheimer's disease, which is characterized by severely diminished levels of acetylcholine in the brain (Wynn and Cummings 2004) . Recent studies suggest that acetylcholinesterase inhibitors have other pharmacological properties, such as neuroprotective and anti-inflammatory effects (Takada et al. 2003; Pollak et al. 2005; Noh et al. 2009; Shen et al. 2010; Jiang et al. 2013) . Donepezil and galantamine are thought to also promote neuronal differentiation both in vitro and in vivo (Jin et al. 2006; Kotani et al. 2006; Kita et al. 2014) . Using oligodendrocyte progenitor cells, we have previously reported that donepezil stimulates oligodendrocyte differentiation and myelin gene expression (Imamura et al. 2015) . In this study, we investigated the effects of donepezil on self-renewal activity, proliferation, differentiation, and survival of primary mouse embryonic NSCs. Our results led to the discovery of a previously unknown effect of donepezil, namely its ability to stimulate the differentiation of NSCs into oligodendrocytes and neurons at the expense of astrogenesis. We further demonstrate that donepezil efficiently increases the numbers of mature oligodendrocytes and reduces astrocyte differentiation by suppressing the activation of the STAT and SMAD signaling pathways, which are key regulation pathways in the astrogenesis of NSCs.
Material and methods
Reagents Donepezil hydrochloride [(AE)-2-[(1-benzylpiperidin-4-yl) methyl]-5,6-dimethoxy-indan-1-one monohydrochloride] was kindly supplied by Eisai Co., Ltd. (Tokyo, Japan). Donepezil hydrochloride was dissolved in distilled water (H 2 O) and H 2 O was used as a vehicle control for these agents. 4
0 ,6-Diamidino-2-phenylindole (DAPI), human platelet-derived growth factor-AA (PDGF-AA), poly-L-ornithine hydrobromide, and human epidermal growth factor (EGF) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Human fibroblast growth factor (FGF) basic was obtained from R&D Systems (Minneapolis, MI, USA). Laminin was purchased from BD Biosciences (Bedford, MA, USA).
Cell culture
All animal experiments were performed in accordance with a protocol approved by the Animal Care and Use Committee of the National Defense Medical College. Pregnant ICR mice were obtained from CLEA Japan (Tokyo, Japan). The ganglionic eminences were removed from E14.5 mouse embryos and mechanically dissociated with a 200-lL pipette. The dissociated cells were then seeded at a density of 10 5 cells/mL into serum-free growth medium containing Dulbecco's modified Eagle's medium/F12
(1 : 1), glucose (0.6%), B27 (1%), streptomycin (100 U/mL), and penicillin (100 U/mL). All cell culture reagents except for glucose were purchased from Invitrogen (Carlsbad, CA, USA). Glucose was purchased from Nacalai Tesque (Kyoto, Japan). The cells were grown in the presence of EGF (20 ng/mL) and FGF-2 (20 ng/mL) for 7 days. At each passage, the numbers of neurospheres were counted and their diameters were measured. Only spheres larger than 50 lm in diameter were counted.
Cell treatment
To observe the effect of donepezil on the growth of NSCs, GEderived NSCs were continuously treated with different concentrations (0.3-80 lM) of donepezil in proliferation media for 7 days. To precisely evaluate cell growth capacity, NSCs were plated at clonal density (30 000 cells/mL) with 20 lM donepezil for 7 days.
To determine the self-renewal, the primary neurospheres were dissociated into a single-cell suspension and the resultant cells were plated at clonal density with 20 lM donepezil for 7 days. For cell proliferation assays, donepezil-treated neurospheres were pulsed with 10 lM 5-ethynyl-20-deoxyuridine (EdU, Invitrogen) for 18 h after 2 days in culture and subsequently dissociated with Accutase (Invitrogen) and plated onto poly-L-lysine/laminin-coated culture dishes for 30 min. EdU incorporation was determined using the Click-iT EdU kit (Invitrogen) according to the manufacturer's instructions. The number of EdU-labeled cells was divided by the total number of DAPI-positive nuclei to determine the percentage of proliferating cells. Apoptotic cells in neurospheres were identified 7 days after treatment with donepezil using the terminal deoxynucleotidyl transferase mediated dUTP nick-end in situ labeling (TUNEL), which was performed using the ApopTag methodology according to the manufacturer's instructions (ApopTag Plus Fluorescein In Situ Apoptosis Detection Kit, Millipore, Billerica, MA, USA). For the differentiation assay, the neurospheres were dissociated and cultured as monolayers on poly-Lornithine/laminin-coated culture dishes. NSCs were then induced to differentiate into neurons, astrocytes, and oligodendrocytes by removing the mitogens from the medium and culturing them with 0.5% fetal bovine serum (FBS) for 5 days in the presence of 20 lM donepezil. Alternatively, more astrocyte differentiation was induced using 10% FBS for 5 days in the presence of 20 lM donepezil.
RNA isolation and real-time PCR
For RNA isolation, NSCs were seeded onto poly-L-ornithine-and laminin-coated dishes in Dulbecco's modified Eagle's medium/F12 medium with B27 supplement containing FGF2 and EGF. The following day, differentiation was initiated in the presence or absence of donepezil by growing the cells in differentiation medium for 24 h. Total RNA was extracted following the ISOGEN isolation protocol (Nippon Gene, Tokyo, Japan) and 500-ng aliquots were reverse transcribed with random hexamer primers using the PrimeScript RT Reagent Kit (Takara, Shiga, Japan Protein isolation and western blot analysis Cultured cells were washed twice with phosphate-buffered saline (PBS) and lysed using hot lysis buffer containing 10 mM Tris-HCl (pH 7.4), 1% sodium dodecylsulfate, 0.1 mM sodium orthovanadate, and complete protease inhibitor cocktail (Roche, Basel, Switzerland). The lysates were then purified by centrifugation at 13 000 g for 15 min. The protein concentration of each lysate sample was measured using a micro bicinchoninic acid protein assay (Pierce, Rockford, IL, USA). Western blotting was done as described previously (Imamura et al. 2008 Relative expression levels of the proteins were quantified using an LAS3000 digital imaging system (Fujifilm, Kanagawa, Japan).
Immunoblots were stripped and re-probed using Restore Western Blot Stripping Solution (Nacalai Tesque).
Immunocytochemistry
Differentiating neural cells were cultured on poly-L-ornithine/ laminin-coated culture dishes for 5 days. Neurospheres were cytospun onto glass slides (Frontier FRC-05; Matsunami, Osaka, Japan) using a Cytospin 3 Cytocentrifuge (Thermo Fisher Scientific, Cheshire, UK) at 1000 rpm for 2 min. Prior to staining, the cells were fixed using 4% paraformaldehyde in PBS for 20 min at 25°C. Fixed cells were washed three times with PBS and preincubated in PBS containing 5% normal goat serum and 0.1% Triton X-100 for 30 min. They were then incubated with primary antibodies in 1% normal goat serum and 0.1% Triton X-100 overnight at 4°C. Primary antibodies used were as follows: mouse anti-bIII-tubulin (MMS-435P, 1 : 500; Covance, Princeton, NJ, USA), rabbit anti-GFAP (N1506, 1 : 10; DAKO), mouse anti-GFAP (G3893, 1 : 500; Sigma), rat anti-MBP (MAB386, 1 : 250, Millipore), rabbit anti-activated caspase-3 (#9661, 1 : 400; Cell Signaling Technology), mouse anti-A2B5 (MAB312, 1 : 250; Millipore), mouse anti-O4 (1 : 5; kindly provided by B. A. Barres), mouse antinestin (MAB353 1 : 500; Millipore), goat anti-DCX (sc-8066, 1 : 500; Santa Cruz Biotechnology), rabbit anti-Sox2 (AB5603, 1 : 1000; Millipore), rat anti-PDGFR (558774, 1 : 1000; BD Biosciences), and rabbit anti-NG2 (AB5320, 1 : 500; Millipore). After primary antibody incubation, the cells were washed three times and then incubated with secondary antibodies for 1 h at 25°C. Secondary antibodies used were: Alexa Fluor 488 goat anti-mouse IgM (A21042, 1 : 1000; Molecular Probes, Eugene, OR, USA), Alexa Fluor 488 goat anti-rat IgG (A11006, 1 : 1000; Molecular Probes), Alexa Fluor 555 goat anti-mouse IgG (A21424, 1 : 1000; Molecular Probes), and Alexa Fluor 555 goat anti-rabbit IgG (A21429, 1 : 1000; Molecular Probes). Fluorescent-labeled cells were imaged using the Nikon C1 system running on a Nikon Eclipse TE2000 inverted microscope (Nikon, Tokyo, Japan). For quantitation of cultured cells, positive cells were counted in 10 randomly selected visual fields per sample and the results were expressed as a percentage to the total cells indicated by DAPI staining. The images were processed using Photoshop CC software (Adobe Systems Inc., San Jose, CA, USA).
Transfection and luciferase assay STAT signaling was quantified using the Cignal STAT3 Reporter Assay Kit (SABiosciences, Frederick, MD, USA). NSCs were plated at a density of 2.5 9 10 5 cells/well in four-well plates (TOHO, Tokyo, Japan) the day before transfection. Transfections were performed using Lipofectamine LTX (Invitrogen) according to the manufacturer's protocol. Briefly, 2 lL of Lipofectamine LTX reagent was used for every 1 lg of transfected DNA in 100 lL of Opti-MEM (Invitrogen). The Lipofectamine LTX-DNA mixture was incubated for 5 min at 25°C and added to the cells. Eight hours after transfection, cells were switched from growth media to differentiation media and then cultured in FBS in the presence or absence of donepezil. After 48 h, cells were harvested in passive lysis buffer and analyzed with a dual-luciferase reporter assay system (Promega, Madison, WI, USA) according to the manufacturer's instructions. Luciferase activity was measured with a TECAN Infinite M200Pro luminometer (Tecan, M€ annedorf, Switzerland) and normalized to the activity of Renilla luciferase in the same well.
Statistical analysis
All experiments were conducted at least in triplicate and data in figures are expressed as means and standard deviations. Statistical significance was determined using Student's t-test in all studies. Significance was determined using p < 0.05.
Results
Effects of donepezil on self-renewal of embryonic cortical stem cells NSCs were harvested from the ganglionic eminences (GEs) of E14.5 mice using a neurosphere system. Neurospheres are aggregate of heterogeneous cells including neural stem and progenitor cells, as well as already differentiated cells. To determine the population of neurosphere-forming cells, neurospheres were collected by cytospin and immunostained for nestin and Sox2 (markers for neural stem cell), Tuj1 and DCX (markers for immature neurons/neuroblasts), A2B5, PDGFRa, and NG2 (markers for OPCs), GFAP (marker for astrocyte). We found that more than 90% of the cultured NSCs were nestin positive and Sox2 positive. Furthermore, A2B5 and PDGFRa were moderately expressed in neurospheres (57.4 AE 3.2% and 24.8 AE 4.1%, respectively). The differentiation markers Tuj1 and GFAP were slightly expressed (1.4 AE 0.9% and 0.9 AE 0.2%, respectively). The percentage of neurosphere cells expressing these markers was quantitated as shown in Figure S1 . To observe the effect of donepezil on the growth of NSCs, GE-derived NSCs were continuously treated with different concentrations (0.3-80 lM) of donepezil in proliferation media over 7 days. The primary spheres formed in 80 and 20 lM donepeziltreated cultures were significantly smaller than those formed in control cultures (Fig. 1a) . To precisely evaluate cell growth capacity, we generated neurospheres in a low-density culture (30 000 cells/mL) in the presence of 20 lM donepezil for 7 days. The numbers and sizes of primary spheres were significantly decreased in donepezil-treated cultures compared to those in control cultures, from 616.3 AE 71.7% to 236.7 AE 39.7%; p < 0.01 ( Fig. 1b and  d) . The secondary spheres generated from primary spheres were also significantly smaller in donepezil-treated cultures than in control cultures (Fig. 1e) . To determine the selfrenewal ability of the cultured NSCs in this experiment, we counted the numbers of secondary spheres, which were significantly decreased in donepezil-treated cultures compared to control cultures, indicating a decreased self-renewal ability following donepezil treatment (Fig. 1c , from 252.7 AE 33.1% to 88.7 AE 19.6%; p < 0.01). Stem cell self-renewal can be regulated by several different mechanisms, including cell proliferation, survival, or differentiation (Molofsky et al. 2004) . We first analyzed cell proliferation by measuring EdU incorporation into neurospheres for 18 h. Neurospheres were subsequently dissociated and acutely plated for 1 h on substrate-coated dishes. Immunostaining revealed no significant differences in the numbers of EdU-positive cells between controls and the donepezil-treated groups ( Fig. 2a and b) , indicating that donepezil does not affect cell proliferation. To identify apoptotic cells, dissociated cells from neurospheres were plated on substrate-coated dishes and subjected to TUNEL assay. As shown in Fig. 2c and d, the numbers of TUNELpositive cells were significantly increased by treatment with donepezil (from 1.11 AE 0.3% to 4.81 AE 0.9%; p < 0.01), indicating an increased apoptotic response to donepezil exposure. Western blot analysis of neurosphere-derived cells further confirmed apoptosis, by revealing increased cleaved caspase-3 (CC3) expression in donepezil-treated cultures compared to control cultures (Fig. 2e) . The PI3K/Akt signaling pathway plays a critical role in mediating survival signals in a wide range of neuronal cell types. Thus, we extracted and examined several Akt pathway-related proteins from control-and donepezil-treated cultures. The amounts of phosphorylated mTOR (Ser2448), Akt (Ser473), and Bad (Ser136) in NSCs from donepezil-treated cultures were significantly lower than those from control cultures. Treatment with donepezil had little effect on the levels of mTOR, Akt1, and Bad, suggesting that the donepezil-mediated inhibition of NSC expansion was associated with increased apoptosis, which is preceded by the activation of the PI3K/ Akt signaling pathway ( Fig. 2e and f) . In order to identify the apoptotic cell types following donepezil treatment, neurospheres were collected by cytospin and co-immunostained antibodies against CC3 and the cell-type-specific markers nestin for neural stem cells, DCX for immature neurons/ neuroblasts, Tuj1 for immature neurons, GFAP for astrocytes, A2B5 for glial progenitors, and PDGFRa for OPCs. As shown in Fig. 2g and h, CC3 was found to co-localize extensively with A2B5 and nestin. CC3 immunoreactivity was also present in PDGFRa-and GFAP-positive cells. By contrast, a small proportion of CC3 co-localization was detected with markers such as DCX and Tuj1. These results indicate that apoptosis seemed to occur randomly. We observed no significant differences in cell composition within the neurosphere between controls and the donepeziltreated groups (Fig. S2) .
Donepezil promotes oligodendrocyte differentiation of NSCs and myelin-associated protein expression
To determine the effect of donepezil on differentiation of NSCs into oligodendrocytes, neurosphere-derived NSCs were differentiated with or without 20 lM donepezil in the growth factor-withdrawn medium for 5 days. They were then immunolabeled for oligodendrocyte progenitor marker, NG2, for the immature oligodendrocyte marker, O4, and for the mature oligodendrocyte marker, MBP. As shown in Fig. 3a d, the numbers of NG2-(from 10.5 AE 0.8% to 21.6 AE 2.4%; p < 0.01), O4-(from 4.05 AE 1.5% to 11.5 AE 0.8%; p < 0.01), and MBP-positive cells (from 3.13 AE 0.6% to 6.77 AE 0.4%; p < 0.01) were significantly increased following treatment with donepezil. These results imply that donepezil can promote the differentiation of NSCs into OPCs and subsequently oligodendrocytes.
Oligodendrocyte differentiation is a sequential multistep process in which cells change from progenitor cells to premature oligodendrocytes and finally into mature myelinforming oligodendrocytes. Each of these cell types is distinguished by the expression of stage-specific marker proteins (Pfeiffer et al. 1993; Armstrong 1998; Miller 2002; Zuchero and Barres 2013) . We assessed the effect of 1-5 days of treatment with donepezil in differentiation medium on the expression of major myelin-specific proteins using western blots. As shown in Fig. 3e , MAG was not detected at up to 3 days of NSC differentiation in control cultures. In contrast, donepezil-induced changes in MAG levels were detected after 2 days and became more evident with increasing treatment time. Increased oligodendrocyte differentiation following donepezil treatment was further confirmed by time-dependent increases in the expression levels of CNPase and MBP. Collectively, these results suggest that donepezil greatly enhances oligodendrocyte differentiation and induces the expression of myelinassociated proteins. To analyze the influence of donepezil on cell proliferation under differentiation conditions, we measured EdU incorporation during an 18-h incubation period that started either 24 or 72 h after differentiation. We observed no significant differences in the numbers of EdU-positive cells between controls and the donepezil-treated groups (Fig. 3f) . We can thus rule out effects of donepezil on cell proliferation. We next examined whether donepezil treatment altered the incidence of apoptosis. Apoptotic cell death following donepezil treatment for 1 or 3 days was detected using CC3 immunolabeling (Fig. 3g ). There were no statistically significant differences in the numbers of apoptotic cells between controls and the donepezil-treated groups at either time point. Taken together, these data indicate that donepezil increased the numbers of mature oligodendrocytes by promoting the differentiation of NSCs without affecting cell survival or proliferation.
Effects of donepezil on neuronal and astrocytic differentiation of NSCs
NSCs are multipotent cells that self-renew and differentiate into neurons, astrocytes, and oligodendrocytes Weiss 1992, 1996) . To determine whether donepezil participates in the neuronal and astrocytic differentiation of NSCs, we used immunocytochemistry to determine the expression levels of DCX (immature neuron/neuroblast), Tuj1 (immature neuron), and GFAP (astrocyte) marker proteins. The numbers of GFAP-positive astrocytes (from 24.6 AE 2.4% to 11.5 AE 1.7%; p < 0.05) were decreased following 5 days of donepezil treatment, whereas the numbers of DCX-(from 11.5 AE 1.3% to 26.0 AE 3.9%; p < 0.05) and Tuj1-positive neurons (from 6.77 AE 1.3% to 11.9 AE 2.1%; p < 0.05) were increased ( Fig. 4a-d) . Western blot analysis also confirmed the increased expression of Tuj1 and the decreased expression of GFAP, suggesting that donepezil stimulates neuronal differentiation and inhibits astrogenesis (Fig. 4e) . To determine concentration-dependent effects of donepezil on NSC differentiation, NSCs were continuously treated with different concentrations (0.02-80 lM) of donepezil in differentiation medium for 5 days and analyzed by western blotting. Donepezil increased the expression levels of MAG and MBP at 20 and 5 lM, but did not have the same effect at 0.02-1.2 lM. This result is consistent with that of our previous report, which showed that relatively high concentrations of donepezil can promote oligodendrocyte differentiation. These data indicate that donepezil only works over a very narrow range of concentrations. Western blotting also revealed that 20 lM donepezil increased the expression of Tuj1, which was accompanied by a reduction in the expression levels of GFAP (Fig. 4f) . These results indicate that donepezil stimulates NSC differentiation into oligodendrocytes and neurons at the expense of astrogenesis. Donepezil stimulates mRNA expression of myelin-associated genes To address whether the donepezil-induced myelin-associated protein expression occurs at the transcriptional level, we performed real-time PCR to examine the expression of major myelin genes 24 h after differentiation. The mRNA levels of MAG, MBP, proteolipid protein, CNPase, myelin gene regulatory factor, and PDGFRa were up-regulated more than twofold following treatment with donepezil. Interestingly, the expression of inhibitor of differentiation 4 mRNA, which is a negative transcriptional regulator of myelin gene expression, significantly decreased with donepezil treatment (Fig. 5) . As evident from immunostaining and western blot in Fig. 4 , donepezil treatment increased DCX and Tuj1 mRNA levels more than twofold, while the mRNA levels of the astrocyte-specific protein GFAP were significantly decreased by 30%. Moreover, mRNA levels for the astrocyte marker S100b and glutamate aspartate transporter were significantly down-regulated by treatment with donepezil. These results indicate that donepezil stimulates mRNA expression of myelin and neuroblasts/immature neuronal marker proteins and inhibits mRNA expression of astrocyte marker proteins in NSCs.
Donepezil promotes oligodendrocyte differentiation even under astrocytic-endorsing conditions
It has been shown that increased FBS concentrations enhance astrocyte differentiation (Raff et al. 1983) . When neurosphere-derived NSCs were differentiated in medium containing 10% FBS, the expression levels of GFAP were significantly higher than they were in 0.5% FBS-containing culture medium (Fig. 6a) . We next examined whether donepezil can stimulate oligodendrocyte differentiation under these culture conditions. As shown in Fig. 6b-d , donepezil decreased the number of GFAP-positive astrocytes in 10% FBS-containing medium (from 43.2 AE 2.6% to 21.6 AE 6.4%; p < 0.01) while increasing oligodendrocyte differentiation of NSCs (from 0.13 AE 0.1% to 2.79 AE 0.8%; p < 0.05). Western blot analysis also revealed that donepezil increased the levels of myelin markers MAG and MBP and decreased the levels of astrocyte marker GFAP in a timedependent fashion (Fig. 6f) . We were not able to find any significant difference in the numbers of Tuj1-positive cells between controls and the donepezil-treated groups (Fig. 6e) . Thus, donepezil promotes oligodendrocyte differentiation at the expense of astrogenesis under astrocyte-inducing . NSCs were differentiated with or without donepezil for 24 h and the mRNA expression levels of myelinassociated glycoprotein (MAG), myelin basic protein (MBP), proteolipid protein (PLP), CNPase, myelin gene regulatory factor (MYRF), platelet-derived growth factor receptor PDGFRa), inhibitor of differentiation 4 (Id4), doublecortin (DCX), Tuj1, glial fibrillary acidic protein (GFAP), S100b, and glutamate aspartate transporter (GLAST) relative to that of b-actin mRNA were investigated by real-time PCR. Note that donepezil stimulates the expression of myelin genes and transcriptional factors that regulate oligodendrocyte differentiation and myelination. Donepezil also stimulates mRNA expression of neuronal marker proteins and inhibits mRNA expression of astrocyte marker proteins in NSCs. Ctrl, control; DNP, donepezil. **p < 0.01 versus control (Student's t-test).
conditions. We next investigated the mechanisms by which donepezil decreased astrocyte differentiation. The STAT and SMAD signaling pathways have been suggested to play regulatory roles in astrocyte differentiation of NSCs (Nakashima et al. 1999) . The activation of STAT3 and SMAD1/5/9 pathways is mediated by serine phosphorylation of these proteins. We analyzed STAT3 and SMAD1/5/9 activation in 10% FBS-treated NSCs by western blotting of total cell lysates. As shown in Fig. 6g and h, donepezil decreased the levels of phosphorylated STAT3 and SMAD1/ 5/9 under astrocyte differentiation conditions. These results suggest that the suppression of STAT3 and SMAD1/5/9 activation by donepezil may inhibit astrogenesis and promote oligodendrocyte differentiation in NSCs. To further confirm the inhibitory effect of donepezil on the activation of STAT3, we measured STAT3-mediated transcriptional activity using a luciferase reporter construct containing a functional STAT3-specific binding element. As expected, the transcriptional activity of STAT3 was more suppressed in donepeziltreated NSCs than in controls, indicating a decrease in STAT3 binding to its response element (Fig. 6i ).
Discussion
In this study, we provide evidence that donepezil treatment in NSCs causes reduced self-renewal ability and increased apoptosis without affecting their proliferation. This was found to be due at least in part to the inhibition of the AktBad signaling pathway. Our pharmacological studies also showed that donepezil led to reduced numbers of astrocytes and increased numbers of oligodendrocytes and neurons in a dose-and time-dependent manner. Moreover, we found that donepezil promotes oligodendrocyte differentiation by preventing the activation of the STAT and SMAD signaling pathways, which are key pathways for the regulation of astrocyte differentiation of NSCs. Oligodendrocytes are myelin-forming cells of the CNS that arise from OPCs and are responsible for myelination and remyelination (Huang et al. 2011) . OPCs can be generated from multipotent NSCs of the adult SVZ (Levison and Goldman 1993; Doetsch et al. 1999) . Demyelination occurs in many neurological diseases, such as MS and spinal cord injury (Franklin and ffrench-Constant 2008) . Current strategies for the treatment of demyelinating disease predominantly target inflammation by modulating the immune system (Rodgers et al. 2013) . However, these strategies only have limited and temporary effects. Increasing evidence suggests that NSCs and OPCs are able to proliferate and differentiate into cells of the oligodendrocyte lineage and are recruited to demyelinated regions of the CNS in patients with MS and in murine demyelination models Picard-Riera et al. 2002; Menn et al. 2006; NaitOumesmar et al. 2007 ). However, they fail to differentiate and mature into myelinating oligodendrocytes and are unable to remyelinate damaged axons, possibly because of inhibitory signals within the demyelinated lesions (Wolswijk 1998 (Wolswijk , 2002 Chang et al. 2000 Chang et al. , 2002 Totoiu and Keirstead 2005; Kuhlmann et al. 2008) . Therefore, direct differentiation of endogenous NSCs or OPCs into myelin-producing oligodendrocytes is a major challenge for the treatment of conditions stemming from oligodendrocyte and myelin dysfunction. Several studies suggest that pharmacological agents can regulate the differentiation of NSCs or OPCs into oligodendrocytes. For example, muscarinic receptor antagonists such as benztropine and clemastine, which are orally available approved drugs, can induce OPC differentiation, remyelination, and functional recovery when administered in a clinically relevant model of multiple sclerosis (Deshmukh et al. 2013; Mei et al. 2014) . Using mouse epiblast stem cell-derived OPCs, Najm et al. (2015) have demonstrated that clobetasol, a potent topical corticosteroid, and miconazole, a topical antifungal agent, enhance OPC differentiation into oligodendrocytes. Their report indicates that clobetasol and miconazole are able to enhance remyelination and significantly reduce disease severity in mouse models of MS (Najm et al. 2015) . Aspirin has also been discovered to induce the differentiation of cultured NSCs into OPCs and oligodendrocytes. It is also known to induce the proliferation and differentiation of OPCs and to attenuate demyelination following cerebral ischemic lesions (Chen et al. 2014) . Interestingly, many medical herbs, including Chimpi, which is isolated from the Japanese traditional herbal medicine ninjin'youeito, are reported to enhance OPC differentiation and functional recovery from demyelination in cuprizonetreated mice (Seiwa et al. 2007; Asou et al. 2011) .
In order to discover small-molecule compounds that can selectively differentiate OPCs into oligodendrocytes, we have previously screened existing drug libraries using a cellbased phenotypic screening assay. We found that donepezil, a medicine used for the treatment of Alzheimer's disease, significantly induces the expression of myelin-related genes and stimulates the differentiation of OPCs into mature oligodendrocytes. We also observed that donepezil significantly stimulates the differentiation of NSCs into mature oligodendrocytes and immature neurons/neuroblasts under differentiation conditions. Although our studies were only performed using embryonic mouse NSC-derived neurospheres, which are widely used in vitro, it is reasonable to expect that donepezil may also influence NSCs to adopt an OPC fate and induce oligodendrocyte myelination in vivo. Indeed, donepezil enhances NSC proliferation and hippocampal neurogenesis and improves cognition in aged mice (Itou et al. 2011) . More importantly, it has been reported that donepezil improves cognitive symptoms in MS and EAE mice (Krupp et al. 2004; D'Intino et al. 2005) . Interestingly, cognitive impairment in MS has been demonstrated to be related to demyelination in studies using imaging analysis (Filippi et al. 2010; Mesaros et al. 2012) . It was also suggested that learning and memory impairment in EAE mice is caused by myelin damage (Sun et al. 2015) . In this report, the inhibition of LINGO-1 (leucine-rich repeat and Ig domain-containing NOGO (neurite outgrowth inhibitor) receptor-interacting protein 1) using an antibody led to a significant improvement in learning and memory in EAE Cignal STAT3 reporter (containing both the inducible STAT3-responsive firefly luciferase construct and constitutively expressing Renilla luciferase construct) and exposed to 20 lM donepezil for 48 h under differentiation conditions. STAT3 reporter activity was performed measured in cell lysates using the dual-luciferase reporter assay system. The relative luciferase activity of each sample was normalized to the Renilla luciferase activity. Note that STAT3 transcriptional activity was decreased by donepezil treatment. Ctrl, control; DNP, donepezil. b-actin was used as an internal control. *p < 0.05, **p < 0.01 versus control (Student's t-test). Scale bar = 50 lm.
mice and increased MBP expression. Furthermore, this LINGO-1 inhibition activated the AKT/mTOR signaling pathway, which is known to promote remyelination. Unfortunately, we did not detect a clear effect of donepezil on Akt/ mTOR pathway under differentiation conditions. In fact, we observed a down-regulation of this pathway under proliferation conditions. Further investigation is necessary to elucidate the molecular mechanisms controlling oligodendrocyte differentiation and maturation by donepezil. Astrogliosis, which is associated with an inhibition of OPC differentiation and maturation in demyelinated lesions, contributes to the failure of remyelination. It has been reported that the JAK/STAT and BMP/SMAD signaling pathways play important roles in astrogenesis and that inhibition of these pathways promotes oligodendrocyte maturation and remyelination (Bright et al. 1999; Cate et al. 2010; Jablonska et al. 2010; Sabo et al. 2011; Liu et al. 2014) . Our in vitro data indicate that, even under astrocyte-inducing conditions, donepezil can promote the differentiation of cultured NSCs into mature oligodendrocytes. Furthermore, donepezil negatively affects astrocyte differentiation of NSCs through the suppression of STAT and SMAD signaling pathways. Based on these results, we hypothesize that donepezil may be a useful tool for understanding the mechanisms controlling NSC fate determination. We also believe that donepezil inhibits cellular responses that contribute to astrogliosis in demyelinated lesions. Additional studies will be required to determine whether the differentiated oligodendrocytes derived from NSCs by donepezil treatment are capable of being recruited into demyelinated regions and whether they contribute to remyelination in murine demyelination models. It will also be important to investigate whether NSC-derived myelinating oligodendrocytes are able to improve neurological functions under pathological conditions.
In conclusion, the present findings suggest that donepezil may promote oligodendrocyte differentiation and myelinrelated gene expression and also negatively affect astrocyte differentiation of NSCs through the suppression of STAT and SMAD signaling pathways. To our knowledge, the present study is the first evidence that donepezil, a prescribed human medicine, induces the differentiation of NSCs into mature oligodendrocytes, suggesting that this medicine may be used for the development of novel strategies for the prevention and therapy of neurological disorders, especially for multiple sclerosis.
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